Cargando…

A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms

This review describes the research aimed at the development of universal antivenom against elapid neurotoxic snake venoms. The antivenoms produced in Thailand in the 1980s were of low potency, especially against the elapid venoms. This was thought to be due to the low immunogenicity of the α-neuroto...

Descripción completa

Detalles Bibliográficos
Autor principal: Ratanabanangkoon, Kavi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102826/
https://www.ncbi.nlm.nih.gov/pubmed/33968072
http://dx.doi.org/10.3389/fimmu.2021.668328
_version_ 1783689184448348160
author Ratanabanangkoon, Kavi
author_facet Ratanabanangkoon, Kavi
author_sort Ratanabanangkoon, Kavi
collection PubMed
description This review describes the research aimed at the development of universal antivenom against elapid neurotoxic snake venoms. The antivenoms produced in Thailand in the 1980s were of low potency, especially against the elapid venoms. This was thought to be due to the low immunogenicity of the α-neurotoxins, which are the most lethal toxins in these venoms. Comparisons of various α-neurotoxin conjugates and polymers, and also different immunological adjuvants, showed that the adjuvant used is the major determinant in the antibody response in horses. The potent Freund’s adjuvant was not used due to its severe local side-effect in horses. Therefore, a novel immunization protocol termed ‘low dose, low volume multi-site’ was developed for use in horses. This immunization protocol has led to the production of highly potent monospecific antivenoms against several elapid and viperid venoms, and two potent polyspecific antivenoms, one against 4 neurotoxic and another against 3 hematotoxic venoms. The immunization protocol has also led to other improvements in antivenom production including: several fold increases in antiserum potency, a reduction in the time required to reach therapeutically useful antibody titers, a 90% reduction in the amount of venom used, and 100% of the horses responding to the immunization program. This development is partly responsible for significant decrease in the Thailand’s annual snakebite death toll from a few dozens to mostly nil in recent years. Finally, a simple and novel immunization strategy, using a ‘diverse toxin repertoire’ composed of numerous elapid toxin fractions as immunogen, was proposed and tested. This immunization procedure has resulted in the successful production of a widely paraspecific antiserum against at least 36 neurotoxic venoms of 28 species encompassing 10 genera and from 20 countries on four continents, and possibly against all elapid venoms with α-neurotoxins as the lethal toxins. These results indicate that, with optimizations of the composition of the ‘diverse toxin repertoire’, the immunization scheme and antibody fractionation to increase the antivenom neutralizing potency, an effective universal antivenom against the neurotoxic elapid snakes of the world can be produced.
format Online
Article
Text
id pubmed-8102826
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81028262021-05-08 A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms Ratanabanangkoon, Kavi Front Immunol Immunology This review describes the research aimed at the development of universal antivenom against elapid neurotoxic snake venoms. The antivenoms produced in Thailand in the 1980s were of low potency, especially against the elapid venoms. This was thought to be due to the low immunogenicity of the α-neurotoxins, which are the most lethal toxins in these venoms. Comparisons of various α-neurotoxin conjugates and polymers, and also different immunological adjuvants, showed that the adjuvant used is the major determinant in the antibody response in horses. The potent Freund’s adjuvant was not used due to its severe local side-effect in horses. Therefore, a novel immunization protocol termed ‘low dose, low volume multi-site’ was developed for use in horses. This immunization protocol has led to the production of highly potent monospecific antivenoms against several elapid and viperid venoms, and two potent polyspecific antivenoms, one against 4 neurotoxic and another against 3 hematotoxic venoms. The immunization protocol has also led to other improvements in antivenom production including: several fold increases in antiserum potency, a reduction in the time required to reach therapeutically useful antibody titers, a 90% reduction in the amount of venom used, and 100% of the horses responding to the immunization program. This development is partly responsible for significant decrease in the Thailand’s annual snakebite death toll from a few dozens to mostly nil in recent years. Finally, a simple and novel immunization strategy, using a ‘diverse toxin repertoire’ composed of numerous elapid toxin fractions as immunogen, was proposed and tested. This immunization procedure has resulted in the successful production of a widely paraspecific antiserum against at least 36 neurotoxic venoms of 28 species encompassing 10 genera and from 20 countries on four continents, and possibly against all elapid venoms with α-neurotoxins as the lethal toxins. These results indicate that, with optimizations of the composition of the ‘diverse toxin repertoire’, the immunization scheme and antibody fractionation to increase the antivenom neutralizing potency, an effective universal antivenom against the neurotoxic elapid snakes of the world can be produced. Frontiers Media S.A. 2021-04-23 /pmc/articles/PMC8102826/ /pubmed/33968072 http://dx.doi.org/10.3389/fimmu.2021.668328 Text en Copyright © 2021 Ratanabanangkoon https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ratanabanangkoon, Kavi
A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms
title A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms
title_full A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms
title_fullStr A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms
title_full_unstemmed A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms
title_short A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms
title_sort quest for a universal plasma-derived antivenom against all elapid neurotoxic snake venoms
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102826/
https://www.ncbi.nlm.nih.gov/pubmed/33968072
http://dx.doi.org/10.3389/fimmu.2021.668328
work_keys_str_mv AT ratanabanangkoonkavi aquestforauniversalplasmaderivedantivenomagainstallelapidneurotoxicsnakevenoms
AT ratanabanangkoonkavi questforauniversalplasmaderivedantivenomagainstallelapidneurotoxicsnakevenoms